Skip to main content

Table 1 Multivariate analysis of serum biomarkers and overall survival in stage III-IV melanoma patients

From: Tumor microenvironment-derived S100A8/A9 is a novel prognostic biomarker for advanced melanoma patients and during immunotherapy with anti-PD-1 antibodies

 

Training set

Independent validation set

Patients

 

Patients

 

N

%

%

Dead

HR

95% CI

P

N

%

%

Dead

HR

95% CI

P

S100A8/A9

 ≤ 5.5 mg/l

81

71.1

35.8

1

  

170

70.8

22.4

1

  

 > 5.5 mg/l

33

28.9

69.7

2.74

1.37–5.46

.0043

70

29.2

45.7

1.79

1.06–3.02

.030

S100B

 ≤ 0.1 μg/l

80

70.2

35.0

1

  

190

79.2

18.4

1

  

 > 0.1 μg/l

34

29.8

70.6

1.61

0.75–3.43

.22

50

20.8

70.0

3.31

1.82–6.03

<.0001

LDH

 ≤ ULN

84

73.7

40.5

1

  

205

85.4

25.4

1

  

 > ULN

30

26.3

60.0

1.68

0.68–4.12

.26

35

14.6

51.4

1.35

0.72–2.54

.35

  1. NOTE. Multivariate survival analysis included 114 AJCC stage III and stage IV patient cases in the training set, and 240 AJCC stage III and stage IV patient cases in the independent validation set. The models were adjusted for age, sex, and clinical stage
  2. Abbreviation: CI confidence interval, HR hazard ratio, LDH lactate dehydrogenase, N number of patients, P P-value, ULN upper limit of normal